Citation 1:
    Title: Biogen Q1 Results Top Estimates; Lowers FY25 Adj. EPS Outlook | Nasdaq
    URL: https://www.nasdaq.com/articles/biogen-q1-results-top-estimates-lowers-fy25-adj-eps-outlook#:~:text=per%20share%20for%20the%20quarter,estimates%20typically%20exclude%20special%20items
    Location: chars 243–446

Citation 2:
    Title: Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
    URL: https://www.pharmaceutical-technology.com/news/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off/#:~:text=pipeline,the%20same%20period%20last%20year
    Location: chars 633–841

Citation 3:
    Title: Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
    URL: https://www.pharmaceutical-technology.com/news/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off/#:~:text=Alongside%20Skyclarys%2C%20Biogen%E2%80%99s%20rare%20disease,selling%20drug%20in%20Q1%202025
    Location: chars 842–1100

Citation 4:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=Q2%20%E2%80%9924%20Q2%20%E2%80%9923%20%E2%96%B3,%E2%80%94
    Location: chars 1193–1518

Citation 5:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=Multiple%20sclerosis%20,4
    Location: chars 1940–2233

Citation 6:
    Title: Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
    URL: https://www.pharmaceutical-technology.com/news/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off/#:~:text=pipeline,the%20same%20period%20last%20year
    Location: chars 2258–2466

Citation 7:
    Title: Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
    URL: https://www.pharmaceutical-technology.com/news/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off/#:~:text=Alongside%20Skyclarys%2C%20Biogen%E2%80%99s%20rare%20disease,selling%20drug%20in%20Q1%202025
    Location: chars 2791–3049

Citation 8:
    Title: Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
    URL: https://www.pharmaceutical-technology.com/news/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off/#:~:text=One%20of%20those%20assets%20is,due%20to%20Medicare%20discount%20dynamics
    Location: chars 3090–3328

Citation 9:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=Multiple%20sclerosis%20,3
    Location: chars 3441–3734

Citation 10:
    Title: As sales climb, Biogen ‘convinced’ the worst is over for Leqembi | BioPharma Dive
    URL: https://www.biopharmadive.com/news/biogen-earnings-leqembi-sales-lilly-kisunla-alzheimers/723023/#:~:text=Sales%20of%20Biogen%E2%80%99s%20drug%2C%20Leqembi%2C,of%20information%2C%20according%20to%20Viehbacher
    Location: chars 3855–4090

Citation 11:
    Title: Biogen (BIIB) earnings Q3 2024
    URL: https://www.cnbc.com/2024/10/30/biogen-biib-earnings-q3-2024.html#:~:text=Still%2C%20uptake%20of%20Leqembi%20has,S
    Location: chars 4123–4255

Citation 12:
    Title: Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
    URL: https://www.pharmaceutical-technology.com/news/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off/#:~:text=Biogen%20splits%20revenue%20from%20Leqembi,EU
    Location: chars 4292–4503

Citation 13:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=%24534%20%24438%2022,1
    Location: chars 4612–4902

Citation 14:
    Title: As sales climb, Biogen ‘convinced’ the worst is over for Leqembi | BioPharma Dive
    URL: https://www.biopharmadive.com/news/biogen-earnings-leqembi-sales-lilly-kisunla-alzheimers/723023/#:~:text=Biogen%E2%80%99s%20development%20partner%20Eisai%2C%20which,integrated%20healthcare%20systems%20adopt%20Leqembi
    Location: chars 5101–5345

Citation 15:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=%241%2C150%20%241%2C209%20%285%29,%2832
    Location: chars 5564–5871

Citation 16:
    Title: Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges
    URL: https://www.biospectrumasia.com/company-results/83/25587/biogen-reports-q4-and-full-year-2024-results-strong-eps-growth-amid-revenue-challenges.html#:~:text=patient%20base%20since%20the%20end,of%202023
    Location: chars 5939–6169

Citation 17:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=Q2%20%E2%80%9924%20Q2%20%E2%80%9923%20%E2%96%B3,%E2%80%94
    Location: chars 6279–6604

Citation 18:
    Title: Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges
    URL: https://www.biospectrumasia.com/company-results/83/25587/biogen-reports-q4-and-full-year-2024-results-strong-eps-growth-amid-revenue-challenges.html#:~:text=Biogen%E2%80%99s%20key%20expense%20analysis%20for,certain%20segments%20faced%20competitive%20pressures
    Location: chars 7125–7413

Citation 19:
    Title: Biogen : reports fourth quarter and full year 2024 results and provides full year 2025 financial guidance | MarketScreener
    URL: https://www.marketscreener.com/quote/stock/BIOGEN-INC-4853/news/Biogen-reports-fourth-quarter-and-full-year-2024-results-and-provides-full-year-2025-financial-gui-49035048/#:~:text=match%20at%20L245%20,SG%26A%20includes%20higher%20operational%20spending
    Location: chars 7414–7695

Citation 20:
    Title: Biogen Q1 Results Top Estimates; Lowers FY25 Adj. EPS Outlook | Nasdaq
    URL: https://www.nasdaq.com/articles/biogen-q1-results-top-estimates-lowers-fy25-adj-eps-outlook#:~:text=Looking%20ahead%20to%20fiscal%202025%2C,and%20more%20favorable%20foreign%20exchange
    Location: chars 7959–8162

Citation 21:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=Q2%20%E2%80%9924%20Q2%20%E2%80%9923%20%E2%96%B3,%E2%80%94
    Location: chars 8368–8693

Citation 22:
    Title: Biogen : reports fourth quarter and full year 2024 results and provides full year 2025 financial guidance | MarketScreener
    URL: https://www.marketscreener.com/quote/stock/BIOGEN-INC-4853/news/Biogen-reports-fourth-quarter-and-full-year-2024-results-and-provides-full-year-2025-financial-gui-49035048/#:~:text=,SG%26A%20includes%20higher%20operational%20spending
    Location: chars 9015–9276

Citation 23:
    Title: Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off - Pharmaceutical Technology
    URL: https://www.pharmaceutical-technology.com/news/biogens-q1-revenue-soars-past-estimates-as-rare-disease-pivot-pays-off/#:~:text=time
    Location: chars 9510–9680

Citation 24:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=Q2%20%E2%80%9924%20Q2%20%E2%80%9923%20%E2%96%B3,%E2%80%94
    Location: chars 10060–10385

Citation 25:
    Title: Biogen : reports fourth quarter and full year 2024 results and provides full year 2025 financial guidance | MarketScreener
    URL: https://www.marketscreener.com/quote/stock/BIOGEN-INC-4853/news/Biogen-reports-fourth-quarter-and-full-year-2024-results-and-provides-full-year-2025-financial-gui-49035048/#:~:text=match%20at%20L275%20,and%2014.6
    Location: chars 10482–10722

Citation 26:
    Title: Biogen Q1 Results Top Estimates; Lowers FY25 Adj. EPS Outlook | Nasdaq
    URL: https://www.nasdaq.com/articles/biogen-q1-results-top-estimates-lowers-fy25-adj-eps-outlook#:~:text=%28RTTNews%29%20,year%20quarter
    Location: chars 10939–11090

Citation 27:
    Title: Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 – 1stOncology™: Cancer Intelligence Service
    URL: https://www.1stoncology.com/blog/biogen-reports-strong-second-quarter-2024-resultsraises-full-year-2024-financial-guidance-second-quarter-2024-total-revenue-of-2-5-billion-gaap-diluted-eps-of-4-00non-gaap-diluted-eps-of-5-28123464524/#:~:text=Q2%20%E2%80%9924%20Q2%20%E2%80%9923%20%E2%96%B3,%E2%80%94
    Location: chars 11433–11758

Citation 28:
    Title: Biogen : reports fourth quarter and full year 2024 results and provides full year 2025 financial guidance | MarketScreener
    URL: https://www.marketscreener.com/quote/stock/BIOGEN-INC-4853/news/Biogen-reports-fourth-quarter-and-full-year-2024-results-and-provides-full-year-2025-financial-gui-49035048/#:~:text=Full%20year%202025%20financial%20guidance%3A,25
    Location: chars 12040–12296

Citation 29:
    Title: Biogen Q1 Results Top Estimates; Lowers FY25 Adj. EPS Outlook | Nasdaq
    URL: https://www.nasdaq.com/articles/biogen-q1-results-top-estimates-lowers-fy25-adj-eps-outlook#:~:text=Looking%20ahead%20to%20fiscal%202025%2C,and%20more%20favorable%20foreign%20exchange
    Location: chars 12334–12537

Citation 30:
    Title: 
    URL: https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/exhibit991-q22024pressrele.htm#:~:text=%E2%80%A2Second%20quarter%202024%20net%20cash,less%20capital%20expenditures%2C%20was%20%24592%C2%A0million
    Location: chars 13039–13267

Citation 31:
    Title: 
    URL: https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/exhibit991-q22024pressrele.htm#:~:text=%E2%80%A2Second%20quarter%202024%20net%20cash,less%20capital%20expenditures%2C%20was%20%24592%C2%A0million
    Location: chars 13905–14133

